Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Opioids: FDA Asks If Abuse-Deterrence Incentives Are In Line

May 09 2016

• By Derrick Gingery

Related Content

Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Mar 24 2014

FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling

Jan 10 2013

Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says

May 05 2016

Related Companies

Zevra Therapeutics, Inc.

Purdue Pharma L.P.

Pfizer Inc.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window